Shots:

• The agreement involves a clinical trial assessing Novartis’s tropifexor and Pfizer’s compounds- including PF-05221304- PF-06865571 & PF-06835919 for treatment of NASH
• Novartis’ tropifexor (LJN452) is a Farnesoid X receptor (FXR) agonist indicated for NASH and has also received FTD by the US FDA for NASH with liver fibrosis in Oct- 2016
• PF-05221304- PF-06865571 & PF-06835919 are inhibitors of Acetyl CoA-Carboxylase (ACC)- Diacylglycerol O-Acyltransferase 2 (DGAT2) and Ketohexokinase (KHK) Inhibitor respectively. NASH has affected up to 6.5% of population WW- having no current treatment approved

Ref: Novartis | Image: News Utexas